Biomarin Pharmaceutical Inc. expects European patients to begin receiving its gene therapy for a life-threatening blood-clotting disorder before the end of the year, raising the drugmaker’s hopes it can succeed where rival Bluebird Bio Inc. faltered.
The one-time infusion for hemophilia could gain European approval at the end of August after getting a key recommendation in June from a regulatory committee, Biomarin Chief Commercial Officer Jeff Ajer said in an interview. The company will then make a country-by-country push to persuade health systems to pay for it, starting with Germany, with broader agreements likely taking about a year to clinch, he said.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
ALK to exit Turkish market: "It's bad business if all we get is peanuts"
A number of conditions made it unfeasible for the Danish allergy firm to do business in Türkiye, says CEO Carsten Hellmann. Under a calculated and ruthless strategy to focus on markets with momentum, efforts in Italy and Spain have also been reduced.
Genmab postpones crucial cancer candidate decision following Abbvie exit
For the rest of 2022, the Danish biotech firm will share all expenses relating to the development of Duohexabody-CD37 with Abbvie, despite the US-based firm’s decision to withdraw from the collaboration in question.
Genmab says new arbitration builds on a straightforward question
”I think this is a much simpler case than the first arbitration,” says Genmab CEO Jan van de Winkel on the new legal suit brought against Janssen, which stems from a fight Genmab has already lost once.
Top news from MedWatch this week
Miss anything?
Analyst: Upgraded ALK sales guidance could still be beaten
Despite an upgrade, ALK may still beat its own sales guidance, one Sydbank analyst predicts.
Clinical Project Leader/ Sr. Clinical Trial Manager – make a difference and join our mission to bring our IL-22 lead program to patients 
Senior Clinical Trial Manager - Black Swans Exist 
Lead Auditor – Senior Quality Assurance Specialist 
Antibody Engineering Scientist 
Director Regulatory Affairs 
Scientist Radiochemistry 
Experienced Biostatistician 
Open position for a Clinical Trial Manager to join our team at Nykode! 
Clinical Biometrics Oversight Lead 
GMP Compliance Consultant for Eltronic in Ballerup 
IT QA Manager 
Clinical Trial Manager - Black Swans Exist 
Senior Electronics Engineer 
Lead Automation Engineer ABB Sattline/ABB 800XA, AFRY